Colchicine was superior to placebo in reducing cardiovascular events, including MACE in coronary artery disease (RR 0.67; 95% CI 0.54-0.84) and recurrent pericarditis (RR 0.50).
Meta-Analysis (n=15,569)
Does colchicine reduce cardiovascular events in patients with cardiovascular diseases?
Colchicine is an effective anti-inflammatory agent for preventing cardiovascular events across multiple inflammatory cardiac conditions, including pericardial diseases, coronary artery disease, and atrial fibrillation.
Effect estimate: RR 0.67 (95% CI 0.54-0.84)
Absolute Event Rate: 6.3% vs 9%
Aim: Colchicine, a microtubule-disassembling (antitubulin) agent used for centuries for the treatment of gout and autoimmune diseases, is a drug of growing interest in the cardiovascular field. While in the last decades it has become cornerstone of pericarditis treatment, it has also emerged in the last few years as a promising drug in the management of coronary artery disease, atrial fibrillation and heart failure. This systematic review and meta-analysis aimed to assess the efficacy of colchicine in patients with cardiovascular diseases. Methods: Systematic search in electronic databases (MEDLINE/PubMed, Scopus, BioMed Central, the Cochrane Collaboration Database of Randomized Trials, ClinicalTrials.gov, EMBASE, Google Scholar) was performed to identify randomized controlled trials (RCTs) up to February 2021. Random-effects meta-analysis was performed to assess the risk of cardiovascular events, defined according to clinical setting. Results: Among 15,569 pooled patients from 21 RCTs, colchicine was superior to placebo in the reduction of cardiovascular events. In the setting of pericardial diseases, it was associated with a lower risk of recurrent pericarditis (17 vs 34%, RR = 0.50, 95% CI: 0.42–0.60, I2 = 10%). In other studies assessing coronary artery disease patients, colchicine was associated with a reduced risk of major adverse cardiovascular events (MACE) such as myocardial infarction, stroke, cardiovascular death, coronary revascularisation and hospitalization (6.3 vs 9%, RR = 0.67, 95% CI: 0.54–0.84, I2 = 55). Among patients with atrial fibrillation, it was associated with lower rates of recurrence (20 vs 30%, RR = 0.68, 95% CI: 0.58–0.81, I2 = 0). In the single RCT on heart failure, colchicine was not associated with improved NYHA class. Conclusion: Colchicine is a valuable anti-inflammatory agent for the prevention of cardiovascular events in patients with inflammatory cardiac conditions such as pericardial diseases, coronary artery disease and atrial fibrillation.
Casula et al. (Tue,) conducted a meta-analysis in Cardiovascular diseases (n=15,569). Colchicine vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) in patients with coronary artery disease (RR 0.67, 95% CI 0.54-0.84). Colchicine was superior to placebo in reducing cardiovascular events, including MACE in coronary artery disease (RR 0.67; 95% CI 0.54-0.84) and recurrent pericarditis (RR 0.50).